Austin-based Molecular Templates, Inc. is a clinical stage biopharmaceutical company with a mission to combat cancer and other serious diseases through the discovery and development of biologic therapeutics. The company specializes in utilizing its proprietary biologic engineered toxin body (ETB) drug platform to create groundbreaking therapies. Currently, Molecular Templates has several ETB candidates in Phase I clinical trials. One such candidate is MT-8421, which seeks to dismantle TME by directly killing tumor and immune cells. Another candidate, MT-0169, aims to treat patients with relapsed/refractory multiple myeloma. Lastly, MT-6402 is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. Additionally, Bristol Myers Squibb, one of the leading pharmaceutical companies in the world, has partnered with Molecular Templates to further develop novel products containing ETBs directed towards multiple targets. Founded in 2001, Molecular Templates has remained steadfast in its goal of revolutionizing the world of biopharmaceuticals.